Product Name:4-Bromo-2-fluorotoluene

IUPAC Name:4-bromo-2-fluoro-1-methylbenzene

CAS:51436-99-8
Molecular Formula:C7H6BrF
Purity:95%+
Catalog Number:CM253316
Molecular Weight:189.03

Packing Unit Available Stock Price($) Quantity
CM253316-1000g in stock ŗǵů

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:51436-99-8
Molecular Formula:C7H6BrF
Melting Point:-
Smiles Code:C1=C(C(=CC=C1Br)C)F
Density:
Catalog Number:CM253316
Molecular Weight:189.03
Boiling Point:183.2°C at 760 mmHg
MDL No:MFCD00013551
Storage:Store at room temperature.

Category Infos

Benzenes
Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

Column Infos

Crinecerfont
The New England Journal of Medicine publishes the primary CAHtalyst™ Adult Phase 3 study results of Crinecerfont for the treatment of congenital adrenal hyperplasia (CAH). Classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21OHD) is a rare genetic disorder, affected by a lack of cortisol and/or aldosterone. Corticotropin-releasing factor type 1 receptor (CRF1) antagonism is shown to clinically decrease ACTH production and adrenal androgen levels.
Neurocrine's Crinecerfont is an investigational, selective CRF1 antagonist being developed to reduce and control excess adrenocorticotropic hormone (ACTH) and adrenal androgens. The phase 3 study meets primary and important key secondary endpoints, including a significant reduction in androstenedione levels and lowering glucocorticoid dosing.